ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in Patients with Relapsed or Refractory Aggressive B Cell Lymphoma
ImmPACT Bio USA, Inc. announced the US FDA has granted Fast Track Designation for IMPT-314, a potential first-in-class CD19/CD20 CAR T therapy for the treatment of patients with B cell mediated malignancies.
[Phytotherapy Research] To elucidate the underlying antitumor mechanism of lambertianic acid (LA) derived from Pinus koraiensis, the role of cancer metabolism related molecules was investigated in the apoptotic effect of LA in DU145 and PC3 prostate cancer cells.
[Frontiers In Pharmacology] Super enhancer-associated genes and transcription factors were identified from a cell line of metastatic castration-resistant prostate cancer (mCRPC) by the CUT&Tag assay. Differentially expressed genes between mCRPC and primary prostate cancer samples in the GSE35988 dataset were identified.
[Frontiers In Oncology] To facilitate the practical application of human embryonic stem cells (hESCs), scientists established a co-culture system consisting of prostate cancer cell lines and hESCs and investigated the antitumor activity of the supernatant of the co-culture system in vitro and in vivo.